The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: Analysis of the Victorian Admitted Episodes Dataset

Internal Medicine Journal

Volumn 41, Issue 1 B, 2011, Pages 121-129

  Lingaratnam, S ^a   Thursky, K A ^a,b,c   Slavin, M A ^a,b   Kirsa, S W ^a   Bennett, C A ^a   Worth, L J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (United States)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Cancer; Costs; Epidemiology; Neotropenic fever; Surveillance

Indexed keywords

ARTICLE; AUSTRALIA; CANCER CENTER; CANCER THERAPY; ECONOMIC ASPECT; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKEMIA; LYMPHOMA; MORBIDITY; MYELOMA; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CANCER CARE FACILITIES; COSTS AND COST ANALYSIS; CROSS INFECTION; DATABASES, FACTUAL; DIAGNOSIS-RELATED GROUPS; FEVER; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INCIDENCE; INTENSIVE CARE; LENGTH OF STAY; MYCOSES; NEOPLASMS; NEUTROPENIA; PREVALENCE; VICTORIA;

EID: 79251588258     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02343.x     Document Type: Article

References (14)

1. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T etal. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
2. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258-66.
3. Liou SY, Stephens JM, Carpiuc KT, Feng W, Botteman MF, Hay JW. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig 2007; 27: 381-96.
4. Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998; 34: 1857-64.
5. Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther 2003; 1: 23-35.
6. Australian Government of Health and Ageing. National Hospital Cost Data Collection Round 12 (2007-2008). Cost Report 2009.
7. Department of Health (State Government of Victoria). Victorian Admitted Episodes Dataset: 'Febrile Neutropenia separations 2008'. 2009.
8. Carstensen M, Sorensen JB. Outpatient management of febrile neutropenia: time to revise the present treatment strategy. J Support Oncol 2008; 6: 199-208.
9. Duckett SJ, Jackson TJ. The new health insurance rebate: an inefficient way of assisting public hospitals. Med J Aust 2000; 172: 439-42.
10. Perrone J, Hollander JE, Datner EM. Emergency Department evaluation of patients with fever and chemotherapy-induced neutropenia. J Emerg Med 2004; 27: 115-19.
11. Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986; 80: 13-20.
12. Nguyen Q, Reid B. A comparison of two sources of data on fungaemia in two hospitals. HIM J 2006; 34: 88-93.
13. Henderson T, Shepheard J, Sundararajan V. Quality of diagnosis and procedure coding in ICD-10 administrative data. Med Care 2006; 44: 1011-19.
14. McNair P, Duckett S. Funding Victoria's public hospitals: the casemix policy of 2000-2001. Aust Health Rev 2002; 25: 72-98.